Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting restricted stock units and recent 10b5-1 dispositions tied to an AIP insider. The filing lists 5,000 Restricted Stock Units granted 03/15/2022 that are to be sold and two 10b5-1 sales of 5,000 shares each on 04/14/2026 and 04/24/2026 with reported gross proceeds of $100,254.00 and $125,289.50, respectively.
Arteris, Inc. director Saiyed Atiq Raza reported an open‑market sale of 90,000 shares of Common Stock for a weighted average price of $28.713 per share. The sale was executed on May 1, 2026 under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025.
The sold shares are held indirectly through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, where Raza serves as trustee, and this trust held 210,000 shares after the transaction. Separately, Raza directly held 20,839 shares of Arteris common stock following the reported transactions.
AIP notifies the broker-dealer of a proposed sale of 90,000 common shares under a prior option exercise. The filing lists the securities as Previously Exercised Stock Options with proceeds figure $2,606,400.00 and identifies recent 10b5-1 dispositions by related trusts on several dates in 2026.
The notice names Morgan Stanley Smith Barney LLC as the executing broker and lists multiple 10b5-1 sale entries (examples: 106,031 shares on 03/02/2026; 72,940 shares on 04/17/2026), indicating prior rule-based sales from the same trust arrangements.
Arteris, Inc. director Chitkara Raman sold 5,000 shares of Common Stock in an open-market transaction. The sale occurred on April 24, 2026 at a weighted average price of $25.0579 per share, with individual trades between $25.00 and $25.25.
The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. Following this sale, Raman directly holds 147,867 shares of Arteris common stock.
Arteris, Inc. director Antonio J. Viana, through the Viana Family Trust, sold 20,000 shares of Arteris common stock in an open-market transaction at a weighted average price of $26.1117 per share. After the sale, the trust held 124,620 shares indirectly, and Viana held 20,840 shares directly. The sale was executed under a Rule 10b5-1 trading plan adopted on June 10, 2025.
Viana Family Trust U/A DTD 07/12/2007 filed a Rule 144 notice reporting 20,000 shares of Common Stock to be sold on or about 04/24/2026 on NASDAQ. The filing notes prior 10b5-1 sales of 20,000 shares on 04/17/2026 for $442,168.
Insider sale filed on Form 144: reported disposition of 5,000 shares. The filing shows 5,000 restricted stock units granted 03/15/2022 and a 10b5-1 sale of 5,000 common shares on 04/14/2026 reporting proceeds of $100,254.00. The filing lists the broker as Morgan Stanley Smith Barney LLC.
Arteris, Inc. director Saiyed Atiq Raza, through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, reported open‑market sales of a total of 90,000 shares of Arteris common stock at weighted average prices around $22 per share under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions, the trust holds 300,000 shares indirectly, and Raza also holds 20,839 shares directly.
Arteris, Inc. director Antonio J. Viana reported an open‑market sale of common stock through the Viana Family Trust. On April 17, 2026, the trust sold 20,000 shares at a weighted average price of $22.1084 per share under a pre‑arranged Rule 10b5-1 trading plan adopted on June 10, 2025. After this sale, the trust held 144,620 shares of Arteris common stock, while Viana also directly held 20,840 shares, indicating he retains a substantial equity position.